ArticleJournal of the American Statistical Association2024
Controlling Cumulative Adverse Risk in Learning Optimal Dynamic Treatment Regimens.
Article in Journal of the American Statistical Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Simultaneous Feature Selection for Optimal Dynamic Treatment Regimens.Statistics in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Dynamic treatment regimen (DTR) is one of the most important tools to tailor treatment in personalized medicine. For many diseases such as cancer and type 2 diabetes mellitus (T2D), more aggressive treatments can lead to a higher efficacy but may also increase risk. However, few methods for estimating DTRs can take into account both cumulative benefit and risk. In this work, we propose a general statistical learning framework to learn optimal DTRs that maximize the reward outcome while controlling the cumulative adverse risk to be below a pre-specified threshold. We convert this constrained optimization problem into an unconstrained optimization using a Lagrange function. We then solve the latter using either backward learning algorithms or simultaneously over all stages based on constructing a novel multistage ramp loss. Theoretically, we establish Fisher consistency of the proposed method and further obtain non-asymptotic convergence rates for both reward and risk outcomes under the estimated DTRs. The finite sample performance of the proposed method is demonstrated via simulation studies and through an application to a two-stage clinical trial for T2D patients. Supplementary materials for this article are available online.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.